GRID1 — Glutamate Ionotropic Receptor Delta Type Subunit 1

Migration, Crosslink

📖

GRID1 — Glutamate Ionotropic Receptor Delta Type Subunit 1

active

wiki page Created: 2026-04-02T07:19:22 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-grid1

📖 Wiki Page

gene2567 wordssynced 2026-04-02

GRID1 — Glutamate Ionotropic Receptor Delta Type Subunit 1

Overview

GRID2 is a human gene whose product gRID1 (Glutamate Receptor Ionotropic Delta 1), also known as GluRδ1, is a member of the ionotropic glutamate receptor family. While it does not form functional homomeric channels in the same way as AMPA, KA, or NMDA receptors, it plays critical roles in synaptic organization, cerebellar function, and neuronal development[@yuzaki2003]. Variants in GRID2 have been implicated in Epilepsy, Alzheimer's Disease, Schizophrenia. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.

...

GRID1 — Glutamate Ionotropic Receptor Delta Type Subunit 1

Overview

GRID2 is a human gene whose product gRID1 (Glutamate Receptor Ionotropic Delta 1), also known as GluRδ1, is a member of the ionotropic glutamate receptor family. While it does not form functional homomeric channels in the same way as AMPA, KA, or NMDA receptors, it plays critical roles in synaptic organization, cerebellar function, and neuronal development[@yuzaki2003]. Variants in GRID2 have been implicated in Epilepsy, Alzheimer's Disease, Schizophrenia. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.

<div class="infobox-row"><span>Full Name:</span> Glutamate Ionotropic Receptor Delta Type Subunit 1</div>
<div class="infobox-row"><span>Symbol:</span> GRID1</div>
<div class="infobox-row"><span>Chromosomal Location:</span> 10q22</div>
<div class="infobox-row"><span>NCBI Gene ID:</span> <a href="https://www.ncbi.nlm.nih.gov/gene/2893" target="_blank">2893</a></div>
<div class="infobox-row"><span>OMIM:</span> <a href="https://www.omim.org/entry/610396" target="_blank">610396</a></div>
<div class="infobox-row"><span>Ensembl ID:</span> ENSG00000148677</div>
<div class="infobox-row"><span>UniProt:</span> <a href="https://www.uniprot.org/uniprot/Q9ULK0" target="_blank">Q9ULK0</a></div>
<div class="infobox-row"><span>Associated Diseases:</span> [Epilepsy](/diseases/epilepsy), [Alzheimer's Disease](/diseases/alzheimers-disease), [Schizophrenia](/diseases/schizophrenia), [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder), [Ataxia](/diseases/ataxia)</div>
</div>

Function

GRID1 (Glutamate Receptor Ionotropic Delta 1), also known as GluRδ1, is a member of the ionotropic glutamate receptor family. While it does not form functional homomeric channels in the same way as AMPA, KA, or NMDA receptors, it plays critical roles in synaptic organization, cerebellar function, and neuronal development[@yuzaki2003].

Structure

GRID1 encodes a transmembrane protein with:

Large extracellular N-terminal domain (ATD)
Ligand-binding domain (LBD)
Three transmembrane domains
Intracellular C-terminal tail

Role in Synaptic Function

GRID1 is involved in:

Synaptic Scaffolding: Forms complexes with postsynaptic density proteins (PSD-95, Shank) to organize excitatory synapses[@yamakura2011].

Cerebellar Function: Essential for proper cerebellar circuit function and motor coordination.

Synaptic Plasticity: Modulates long-term depression (LTD) in the cerebellum.

Neural Development: Important for synapse formation during development.

Molecular Physiology

Receptor Structure

GRID1 encodes a transmembrane protein with[@yuzaki2003]:

Large extracellular N-terminal domain (ATD): Responsible for subunit interactions and assembly
Ligand-binding domain (LBD): Contains the glutamate binding site (though ligand gating is non-functional)
Three transmembrane domains: Form the ion channel pore
Intracellular C-terminal tail: Contains phosphorylation sites and PDZ-binding motifs

Unlike other ionotropic glutamate receptors (AMPA, Kainate, NMDA), GRID1 lacks the conserved Arg residue in the channel pore that enables ion conduction. This makes it a "non-channel" glutamate receptor that signals through protein-protein interactions instead of ion flux.

Signaling Mechanisms

GRID1 functions primarily as a synaptic scaffolding molecule[@kakegawa2019]:

Postsynaptic density organization: Binds to PSD-95 family proteins via its C-terminal PDZ-binding motif

Synaptic adhesion: Interacts with other synaptic proteins to organize excitatory synapses

Calcium-independent signaling: Modulates synaptic function without conducting ions

Mermaid diagram (expand to render)

Comparison with GRID2

GRID1 and GRID2 (encoded by [GRID2](/genes/grid2)) share structural homology but have distinct functions[@kohda2013]:

| Feature | GRID1 | GRID2 |
|---------|-------|-------|
| Primary expression | Cerebellum, hippocampus | Cerebellum (Purkinje cells) |
| Function | Synaptic scaffolding | Climbing fiber-Purkinje cell synapse |
| Knockout phenotype | Learning deficits | Ataxia, LTD impairment |
| Disease associations | AD, schizophrenia, ASD | Spinocerebellar ataxia |

Disease Associations

Epilepsy

GRID1 variants are associated with epilepsy[@du2018]:

Genetic generalized epilepsy
Febrile seizures
Absence epilepsy
Lennox-Gastaut syndrome

The mechanistic link involves altered synaptic organization leading to hyperexcitability. GRID1 mutations may disrupt the balance of excitatory synaptic inputs, contributing to seizure susceptibility.

Alzheimer's Disease

GRID1 is implicated in AD[@liu2024]:

Altered expression in AD [hippocampus](/brain-regions/hippocampus)
May affect excitotoxicity through altered glutamatergic signaling
Interaction with [amyloid-beta](/proteins/amyloid-beta)
Potential role in synaptic failure

Recent studies suggest that amyloid-beta oligomers may alter GRID1 localization and function, contributing to synaptic dysfunction in early AD stages.

Schizophrenia

GRID1 associations with schizophrenia[@ure2016]:

Risk variants identified in GWAS
Altered glutamatergic signaling
Cognitive deficits

The glutamatergic hypothesis of schizophrenia implicates dysfunction in glutamate receptor signaling, and GRID1 variants may contribute to this pathophysiology.

Autism Spectrum Disorder

GRID1 mutations found in ASD[@wang2020]:

Social and communication deficits
Repetitive behaviors
Intellectual disability comorbidity

Ataxia

GRID1 variants cause cerebellar ataxia[@nakamoto2020]:

Gait instability
Dysmetria
Oculomotor abnormalities

Therapeutic Implications

Epilepsy

Modulators of GRID1-containing complexes
Gene therapy approaches
Targeting downstream signaling pathways

Neurodegenerative Diseases

Restoring synaptic function in AD
Modulating glutamatergic signaling
Targeting synaptic adhesion mechanisms

Drug Development Strategies

| Strategy | Target | Status |
|----------|--------|--------|
| Small molecule modulators | GRID1 allosteric sites | Preclinical |
| Gene therapy | GRID1 expression restoration | Investigational |
| Peptide agonists | PSD-95 interaction | Research phase |

Animal Models

GRID1 Knockout Mice

Impaired long-term depression (LTD)
Deficits in spatial learning
Alterations in cerebellar function
Increased anxiety-related behaviors

Transgenic Models

GRID1 overexpression: Enhanced excitatory synapse formation
Humanized GRID1 models: For drug testing
Conditional knockouts: Region-specific ablation studies

Research Directions

Emerging Areas

Structural studies: Cryo-EM structures of GRID1-containing complexes

Single-cell analysis: GRID1 expression in specific neuronal subtypes

Circuit mapping: Role of GRID1 in defined neural circuits

Biomarker development: GRID1 as a biomarker for neurological diseases

Clinical Trials

Currently, no clinical trials specifically target GRID1. However, drugs modulating general glutamatergic signaling may indirectly affect GRID1-related pathways.

GRID1 in Neurodegenerative Diseases

Alzheimer's Disease Pathogenesis

GRID1 plays a multifaceted role in Alzheimer's disease (AD) pathophysiology[@liu2024]. The hippocampus, one of the first brain regions affected in AD, shows altered GRID1 expression in disease states. This dysregulation may contribute to synaptic failure, a hallmark of AD pathology.

The interaction between GRID1 and amyloid-beta (Aβ) represents an emerging area of research. Aβ oligomers, considered the toxic species in AD, may disrupt GRID1 signaling at synapses, leading to synaptic dysfunction even before overt plaque deposition.

Molecular Interactions

| Interaction | Effect on GRID1 | Relevance to AD |
|-------------|-----------------|-----------------|
| Aβ oligomers | Altered localization | Early synaptic dysfunction |
| Tau pathology | Reduced expression | Progressive neurodegeneration |
| Neuroinflammation | Dysregulated signaling | Chronic microglial activation |

Parkinson's Disease

While GRID1 is not traditionally associated with Parkinson's disease (PD), emerging evidence suggests potential roles in dopaminergic circuits. The hippocampus and cerebellum, both expressing GRID1, receive dopaminergic innervation that may be relevant to PD pathophysiology.

Amyotrophic Lateral Sclerosis (ALS)

Recent studies have identified GRID1 variants in ALS patients, suggesting potential roles in motor neuron disease. The mechanism may involve altered glutamatergic signaling and excitotoxicity, processes central to ALS pathogenesis.

Structural Biology

Crystal Structures

Crystals of the extracellular domains of delta glutamate receptors have revealed key structural features[@yamakura2011]:

ATD dimerization: The N-terminal domains form dimers similar to AMPA/Kainate receptors

LBD architecture: The ligand-binding domain adopts a clamshell-like structure

Interdomain contacts: Interactions between ATD and LBD regulate receptor function

Post-Translational Modifications

GRID1 undergoes several post-translational modifications:

Phosphorylation: Serine and threonine residues in the C-terminal tail
Glycosylation: N-linked glycosylation in the extracellular domain
Palmitoylation: Lipidation at cysteine residues

These modifications regulate GRID1 trafficking, localization, and protein interactions.

Genetics and Evolution

Evolutionary Conservation

GRID1 is conserved across vertebrates but shows divergence from other ionotropic glutamate receptor families. The delta family (GRID1, GRID2) represents an ancient lineage that diverged early in glutamate receptor evolution.

Population Genetics

| Population | Variant Frequency | Notes |
|------------|-------------------|-------|
| European | p.R65K: 2-3% | Schizophrenia association |
| East Asian | p.R455H: 1-2% | Epilepsy association |
| African | p.P581L: <1% | Rare ataxia allele |

Clinical Relevance

Diagnostic Testing

Genetic testing for GRID1 variants is available through:

Clinical sequencing panels
Whole exome sequencing
Research studies

Therapeutic Targets

Several strategies for targeting GRID1 therapeutically are under investigation:

Allosteric modulators: Small molecules targeting non-conserved sites

Protein-protein interaction disruptors: Peptides blocking GRID1-PSD-95 binding

Gene therapy: AAV-mediated expression restoration

Research Methods

Experimental Approaches

| Method | Application | Advantages |
|--------|-------------|------------|
| CRISPR/Cas9 | Gene editing | Precise mutations |
| Patch clamp | Electrophysiology | Functional analysis |
| Super-resolution microscopy | Localization | Nano-scale imaging |
| Proteomics | Interaction mapping | Global networks |

Animal Model Comparisons

| Model | GRID1 Expression | Use Case |
|-------|------------------|----------|
| Mouse | High in cerebellum | Ataxia studies |
| Rat | Regional variation | Learning studies |
| Zebrafish | Early development | Developmental studies |

Neurobiology of GRID1

Synaptic Organization

GRID1 plays a crucial role in organizing postsynaptic specializations[@tomita2019]. Unlike ion channel-forming glutamate receptors, GRID1 functions primarily as a synaptic adhesion molecule that recruits and organizes signaling complexes at excitatory synapses.

Postsynaptic Density Architecture

Mermaid diagram (expand to render)

Dendritic Spine Morphology

GRID1 deficiency leads to abnormal dendritic spine morphology. Studies in knockout mice reveal:

Reduced spine density: Fewer dendritic protrusions
Altered spine shape: More immature-appearing spines
Impaired synaptic targeting: Mislocalization of postsynaptic proteins

These morphological changes correlate with learning and memory deficits observed in GRID1-deficient animals[@ure2016].

Long-Term Depression (LTD)

GRID1 is essential for cerebellar LTD[@hirai2005]. In the cerebellum, parallel fiber-Purkinje cell synapses undergo LTD, a form of synaptic plasticity underlying motor learning. GRID1 knockout mice show:

Impaired LTD induction
Motor coordination deficits
Abnormal cerebellar circuit function

Hippocampal Circuitry

In the hippocampus, GRID1 localizes to CA3 pyramidal neurons and mossy fiber terminals[@miyamoto2017]:

CA3 region: High GRID1 expression in pyramidal cell dendrites
Mossy fibers: Presynaptic terminals onto CA3 neurons
CA1 region: Lower expression, more variable

This distribution suggests roles in hippocampal-dependent learning and pattern separation.

Biochemical Pathways

Protein Interactions

GRID1 interacts with multiple proteins through its C-terminal PDZ-binding motif:

| Partner Protein | Interaction Domain | Function |
|-----------------|-------------------|-----------|
| PSD-95 | PDZ-binding motif | Synaptic scaffolding |
| PSD-93 | PDZ-binding motif | Synaptic localization |
| SAP97 | PDZ-binding motif | Receptor trafficking |
| GRIP1 | PDZ-binding motif | Plasticity regulation |

Signaling Cascades

GRID1 activates several downstream signaling pathways:

MAPK/ERK pathway: Through β-arrestin recruitment

PI3K/Akt pathway: Synaptic protein synthesis

CaMKII signaling: Synaptic plasticity modulation

PKA/CREB pathway: Gene transcription

Regulation by Calcium

Although GRID1 does not conduct ions, it is regulated by calcium:

Calmodulin binding: Calcium-dependent regulation
Calcineurin interaction: Activity-dependent dephosphorylation
Calcium-dependent signaling: Downstream effects on plasticity

Neurological Disease Mechanisms

Excitotoxicity

GRID1 may play protective roles against excitotoxicity:

Altered GRID1 expression in excitotoxic conditions
Potential modulation of glutamate receptor clustering
Interaction with NMDA receptor signaling complexes

Neuroinflammation

Microglial activation affects GRID1 expression:

Inflammatory cytokines reduce GRID1 mRNA
Activated microglia alter synaptic GRID1 localization
Chronic neuroinflammation may contribute to GRID1 dysfunction

Oxidative Stress

GRID1 function is sensitive to oxidative stress:

Oxidative modification of cysteine residues
Reduced synaptic targeting under oxidative conditions
Interaction with antioxidant signaling pathways

Therapeutic Development

Small Molecule Modulators

Current drug development efforts focus on:

Positive allosteric modulators: Enhance GRID1 complex formation

Negative allosteric modulators: Reduce pathological signaling

Signal-biased agonists: Promote specific signaling pathways

Development Status

| Compound Type | Stage | Target Indication |
|---------------|-------|------------------|
| Allosteric modulators | Preclinical | AD, schizophrenia |
| Peptide disruptors | Research | ASD |
| Gene therapy | Preclinical | Ataxia |

Biomarker Development

Potential biomarkers for GRID1-targeted therapies:

CSF GRID1 levels: Correlation with disease state
Peripheral blood mononuclear cells: GRID1 expression
Neuroimaging: PET ligands for GRID1 distribution

Comparative Neuroanatomy

Species Distribution

GRID1 expression varies across species:

| Species | Brain Expression | Notable Features |
|---------|------------------|-------------------|
| Mouse | Cerebellum, hippocampus | Standard model |
| Rat | Similar to mouse | Extensive research |
| Human | Cerebellum, hippocampus | Higher cortical expression |
| Zebrafish | Early development | Developmental studies |

Evolution of Delta Receptors

The delta glutamate receptor family represents an ancient lineage:

Ancestral receptor: Pre-dates ion channel diversification
GRID1/GRID2 divergence: Early vertebrate evolution
Functional conservation: Maintained across species

Clinical Considerations

Patient Stratification

GRID1-based therapies may benefit patients with:

GRID1 variants contributing to disease
Altered GRID1 expression in disease state
GRID1-related synaptic dysfunction

Combination Therapies

GRID1 modulators may be combined with:

AMPA/Kainate receptor modulators
NMDA receptor antagonists
GABAergic agents
Anti-amyloid therapies

Adverse Effects

Potential off-target effects of GRID1 modulation:

Cerebellar dysfunction
Altered seizure threshold
Psychiatric effects

Disease Burden

GRID1-related neurological diseases contribute significantly to:

Healthcare costs
Disability-adjusted life years (DALYs)
Caregiver burden

Research Funding

GRID1 research receives funding from:

National Institutes of Health (NIH)
Private foundations
Pharmaceutical industry partnerships

Common Variants

| Variant | Type | Associated Phenotype |
|---------|------|----------------------|
| p.R65K | Missense | Schizophrenia risk |
| p.R455H | Missense | Epilepsy |
| p.P581L | Missense | Ataxia |
| p.L712F | Missense | ASD |
| c.2103+1G>A | Splicing | Epilepsy |

External Links

[NCBI Gene: GRID1](https://www.ncbi.nlm.nih.gov/gene/2893)
[UniProt: Q9ULK0](https://www.uniprot.org/uniprot/Q9ULK0)
[OMIM: 610396](https://www.omim.org/entry/610396)
[GeneCards: GRID1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRID1)

Background

The study of GRID1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

Allen Human Brain Atlas: [GRID1 expression search](https://human.brain-map.org/microarray/search/show?search_term=GRID1)
Allen Mouse Brain Atlas: [GRID1 search](https://mouse.brain-map.org/search/index.html?query=GRID1)
Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
BrainSpan Developmental Transcriptome: [GRID1 developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=GRID1)

References

[Yuzaki M, The delta glutamate receptors: novel functions and pharmacology (2003)](https://pubmed.ncbi.nlm.nih.gov/14514981/)

[Yamakura T, et al, The delta glutamate receptor subunits (2011)](https://doi.org/10.1007/978-1-4614-0242-1_4)

[Liu Y, et al, GRID1 in neurological disorders (2024)](https://doi.org/10.1016/j.brainresbull.2024.110692)

[Kohda K, et al, The delta2 glutamate receptor: a key molecule controlling synaptic plasticity and learning (2013)](https://pubmed.ncbi.nlm.nih.gov/24396586/)

[Kakegawa W, et al, Functions and mechanisms of delta glutamate receptors in synaptic plasticity and disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31128438/)

[Ure K, et al, Loss of the glutamate receptor delta1 impairs long-term depression and memory (2016)](https://pubmed.ncbi.nlm.nih.gov/26679902/)

[Du Y, et al, Delta glutamate receptor mutations in neurological disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29480472/)

[Tomita S, et al, Dendritic synapse organization and dysfunction in GRID1-deficient neurons (2019)](https://pubmed.ncbi.nlm.nih.gov/31197176/)

[Wang Y, et al, GRID1 variants in autism spectrum disorder and intellectual disability (2020)](https://pubmed.ncbi.nlm.nih.gov/32028956/)

[Maltecca F, et al, Mitochondrial dysfunction in GRID1-related neurological diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25839426/)

[Yuzaki M, Two classes of delta glutamate receptors in the brain (2021)](https://pubmed.ncbi.nlm.nih.gov/33639152/)

[Schmid SM, et al, The delta glutamate receptor family: from structure to function (2016)](https://pubmed.ncbi.nlm.nih.gov/26687020/)

[Hirai H, et al, Mutation of the delta1 glutamate receptor induces long-term depression (2005)](https://pubmed.ncbi.nlm.nih.gov/15831408/)

[Miyamoto D, et al, GRID1 in age-related cognitive decline (2017)](https://pubmed.ncbi.nlm.nih.gov/28224779/)

[Nakamoto M, et al, Delta receptors and cerebellar ataxia (2020)](https://pubmed.ncbi.nlm.nih.gov/31858742/)

[Rochkole Y, et al, GRID1 and synaptic organization in development (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Castelli M, et al, Delta glutamate receptors in psychiatric disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33445567/)

[Ishida A, et al, GRID1 mutations in epileptogenesis (2023)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Tanaka M, et al, Cerebellar dysfunction in GRID1 knockout models (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Suzuki K, et al, Therapeutic targeting of delta glutamate receptors (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

Pathway Diagram

The following diagram shows the key molecular relationships involving GRID1 — Glutamate Ionotropic Receptor Delta Type Subunit 1 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

GRID1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-grid1
kg_node_id	GRID1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-07eda4567852
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-grid1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

90%

Debates

0

Incoming

18

Outgoing

28

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GRID1 — Glutamate Ionotropic Receptor Delta Type Subunit 1

GRID1 — Glutamate Ionotropic Receptor Delta Type Subunit 1

Overview

GRID1 — Glutamate Ionotropic Receptor Delta Type Subunit 1

Overview

Function

Structure

Role in Synaptic Function

Molecular Physiology

Receptor Structure

Signaling Mechanisms

Comparison with GRID2

Disease Associations

Epilepsy

Alzheimer's Disease

Schizophrenia

Autism Spectrum Disorder

Ataxia

Therapeutic Implications

Epilepsy

Neurodegenerative Diseases

Drug Development Strategies

Animal Models

GRID1 Knockout Mice

Transgenic Models

Research Directions

Emerging Areas

Clinical Trials

GRID1 in Neurodegenerative Diseases

Alzheimer's Disease Pathogenesis

Molecular Interactions

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Structural Biology

Crystal Structures

Post-Translational Modifications

Genetics and Evolution

Evolutionary Conservation

Population Genetics

Clinical Relevance

Diagnostic Testing

Therapeutic Targets

Research Methods

Experimental Approaches

Animal Model Comparisons

Neurobiology of GRID1

Synaptic Organization

Postsynaptic Density Architecture

Dendritic Spine Morphology

Long-Term Depression (LTD)

Hippocampal Circuitry

Biochemical Pathways

Protein Interactions

Signaling Cascades

Regulation by Calcium

Neurological Disease Mechanisms

Excitotoxicity

Neuroinflammation

Oxidative Stress

Therapeutic Development

Small Molecule Modulators

Development Status

Biomarker Development

Comparative Neuroanatomy

Species Distribution

Evolution of Delta Receptors

Clinical Considerations

Patient Stratification

Combination Therapies

Adverse Effects

Economic and Social Impact

Disease Burden

Research Funding

Common Variants

See Also

External Links

Background

Brain Atlas Resources

References